Effects of ulinastatin therapy in deep vein thrombosis prevention after brain tumor surgery: A single-center randomized controlled trial

Table 3 Comparison of the secondary end-points

	UTI (n = 180)	Placebo (n = 181)	P value
Coagulation function, mean ± SD
PT (s)	9.25 ± 2.27	15.36 ± 2.81	< 0.001
APTT (s)	21.13 ± 3.28	26.22 ± 3.29	< 0.001
D-D (mg/L)	1.84 ± 0.72	2.41 ± 0.92	< 0.001
FIB (g/L)	2.71 ± 0.49	2.89 ± 0.58	0.002
Pulmonary embolism	3 (1.67%)	1 (0.55%)
Liver function index levels, mean ± SD
ALT (U/L)	39.27 ± 4.16	41.29 ± 4.25	< 0.001
AST (U/L)	28.84 ± 3.26	29.48 ± 3.87	0.09
Renal function index levels, mean ± SD
Scr	54.33 ± 8.21	56.08 ± 9.42	0.06
BUN	6.37 ± 2.95	8.11 ± 3.10	< 0.001

APTT: Activated partial thromboplastin time; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BUN: Blood urea nitrogen; D-D: D-Dimer; FIB: Fibrinogen; PT: Prothrombin time; Scr: Serum creatinine.